Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
- Citation:
- J Clin Oncol vol 26 (10) 1642-9
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- CA32291, CA33601, CA47559, CA47577, CA77406, CA77651, CA77658
- Corr. Author:
- Authors:
- Andrew D Seidman Donald Berry Constance Cirrincione Lyndsay Harris Hyman Muss P Kelly Marcom Grandella Gipson Harold Burstein Diana Lake Charles L Shapiro Peter Ungaro Larry Norton Eric Winer Clifford Hudis
- Networks:
- Study
- CALGB-9840
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Paclitaxel, Receptor, ErbB-2, Trastuzumab